Show simple item record

dc.contributor.authorOkafor, Charles E
dc.contributor.authorEkwunife, Obinna I
dc.contributor.authorNduaguba, Sabina O
dc.date.accessioned2021-03-12T03:26:43Z
dc.date.available2021-03-12T03:26:43Z
dc.date.issued2021
dc.identifier.issn1478-7547
dc.identifier.doi10.1186/s12962-021-00265-9
dc.identifier.urihttp://hdl.handle.net/10072/403110
dc.description.abstractBACKGROUND: While evidence-based recommendations for the management pneumonia in under-5-year-olds at the community level with amoxicillin dispersible tablets (DT) were made by the World Health Organisation, initiatives to promote the integrated community case management (iCCM) of pneumonia through the proprietary and patent medicine vendors (PPMVs) have been poorly utilized in Nigeria, possibly due to low financial support and perceived benefit. This study provides costs, benefits and cost-effectiveness estimates and implications of promoting the iCCM through the PPMVs' education and support. The outcome of this study will help inform healthcare decisions in Nigeria. METHODS: This study was a cost-effectiveness analysis using a simulation-based Markov model. Two approaches were compared, the 'no promotion' and the 'promotion' scenarios. The health outcomes include disability-adjusted life years averted and severe pneumonia hospitalisation cost averted. The costs were expressed in 2019 US dollars. RESULTS: The promotion of iCCM through the PPMVs was very cost effective with an incremental cost-effectiveness ratio of US$143.77 (95% CI US$137.42-150.50)/DALY averted. The promotion will prevent 28,359 cases of severe pneumonia hospitalisation with an estimated healthcare cost of US$390,578. It will also avert 900 deaths in a year. CONCLUSION: Promoting the iCCM for the treatment of pneumonia in children under 5 years through education and support of the PPMVs holds promise to harness the benefits of amoxicillin DT and provide a high return on investment. A nationwide promotion exercise should be considered especially in remote areas of the country.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofpagefrom12
dc.relation.ispartofissue1
dc.relation.ispartofjournalCost Effectiveness and Resource Allocation
dc.relation.ispartofvolume19
dc.subject.fieldofresearchApplied Economics
dc.subject.fieldofresearchcode1402
dc.subject.keywordsAmoxicillin dispersible tablets
dc.subject.keywordsBenefit
dc.subject.keywordsEducation
dc.subject.keywordsNigeria
dc.subject.keywordsProprietary and patent medicine vendors
dc.titlePromoting the integrated community case management of pneumonia in children under 5 years in Nigeria through the proprietary and patent medicine vendors: a cost-effectiveness analysis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationOkafor, CE; Ekwunife, OI; Nduaguba, SO, Promoting the integrated community case management of pneumonia in children under 5 years in Nigeria through the proprietary and patent medicine vendors: a cost-effectiveness analysis, Cost Effectiveness and Resource Allocation, 2021, 19 (1), pp. 12
dcterms.dateAccepted2021-02-11
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2021-03-12T02:56:51Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorOkafor, Charles E.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record